Investor Ideas #Potcasts, #Cannabis News and #Stocks on the Move; Episode 450 (CSE: $CXXI.C) (NASDAQ: $VFF) (TSXV: $RLV.V) (TSXV: $WMD.V)
Listen to the podcast:
https://www.investorideas.com/Audio/Podcasts/2020/080520-StocksToWatch.mp3
Read this in full
at http://www.investorideas.com/news/2020/cannabis-potcasts/08051CXX-VFF-RLV-WMD.asp
Hear Investor ideas cannabis potcast on iTunes
Hear the investor ideas potcast on
Spotify
Today’s podcast overview/transcript:
Good
afternoon and welcome to another episode of Investorideas.com
"Potcast" featuring cannabis news, stocks to watch as well as
insights from thought leaders and experts.
In
today’s podcast we look at a few public company announcements.
C21
Investments Inc. (CSE: CXXI) (OTCQB: CXXIF) announced record revenue at its Nevada
dispensaries for its second quarter ("Q2" ending July 31, 2020) as
well as for the month of July 2020.
Nevada
Retail Highlights:
● Q2
retail revenue sets record for a quarter, surpassing the previous high in Q3 of
last year
● July
sets a monthly revenue record; first month over $3 million at Silver State
dispensaries and best month ever at the Fernley dispensary
● $98.5k
retail revenue run rate per day in July; previous record of $96.5k in June 2020
● $63
average ticket size in Q2
● Phantom Farms
flower continues as Silver State's top SKU – 13 of the top 25 SKUs are the
Company's Oregon brands
Company CEO and President, Sonny
Newman: "We are very pleased with the record Q2 and July performance at
our Nevada dispensaries which is a testament to the dedication of our team. We
are proud to be celebrating our fifth anniversary as Nevada's first licensed
dispensary. Despite beginning the quarter under state-mandated delivery-only
sales, we responded quickly and began operating three complementary sales
channels in May as restrictions eased. Our strong and loyal customer base
continues to mitigate the impact of the pandemic on our Nevada business. While
both dispensaries are performing exceptionally well, our Fernley dispensary
continues to significantly exceed expectations with July recording its best
month of sales to date."
"In the second quarter C21 has
continued to optimize its Oregon operations. As of June, several non-core
Oregon assets are subject to third-party management agreements and nearing the
completion of sale, which will generate cash, and reduce costs and liabilities
from mid-June onwards. With operations streamlined in Oregon, and robust
revenue and EBITDA margins at our Silver State dispensaries, C21 is working to
deepen its presence in Nevada as we continue to make progress in establishing
our debt facility."
"As reported in our recent
year-end financials, our Nevada dispensaries generated an average of
approximately $16 million in revenue and $6 million in adjusted EBITDA per dispensary.
With the ability to replicate and scale both our profitable dispensary model,
and our vertically integrated operations in Nevada, and with 80% of our
cultivation and production facility still untapped, we expect to build on Q2's
record retail revenue and enhance shareholder value moving forward," said
Mr. Newman.
Village
Farms International, Inc. (NASDAQ: VFF) (TSX: VFF) announced that it has executed a binding
agreement to acquire 6.6% of Australia-based Altum International Pty Ltd, one
of the Asia-Pacific's leading cannabinoid platforms, subject to the completion
of certain conditions, which are expected to be finalized in the next several
weeks. Under the terms of the Agreement,
Village Farms has the option to increase its ownership in Altum on similar
terms.
Altum's mission is to bring the
life-changing benefits of cannabinoids (with focus on CBD) to consumers across
the Asia-Pacific region through a comprehensive platform for the large-scale
importation, distribution and marketing of CBD, composed of three channels,
with an overriding focus on regulatory compliance for each specific country
market:
● Proprietary
Consumer Brands – Fully-owned consumer brands, currently consisting of Felix and Co (www.felixandco.com), Kind Cannabis and tsubomi;
● Commercial
Inputs – A range of cost-competitive, compliant and effective premium CBD
ingredients through its LIFE brand
(www.lifecbd.asia), designed for seamless addition to foods, beverages,
cosmetics and other consumer packaged goods; and,
● Retail –
Retail sales and educational and experiential stores for both Altum and partner
products.
●
Altum has initially focused on
opportunities in Hong Kong, which has one of the most progressive attitudes and
regulatory regimes for CBD in the Asia-Pacific region. It has already launched a broad range of CBD
products under its Felix and Co brand
to very favorable customer feedback and strong initial sales traction. In its Commercial Input channel, Altum is
supplying craft brewers for CBD-infused beer, as well as market-wide coffee
chains and juice bars for beverages and edibles, and is in advanced discussions
for supply agreements to provide inputs for a range of other products,
including pet food, cosmetics, and spa products for hotels. In June 2020, Altum opened a boutique café
and retail concept store in Hong Kong named Found
– Asia's first dedicated CBD consumer outlet. Altum plans to pursue its
business strategy throughout the Asia-Pacific region, including but not limited
to Greater China, Japan, South Korea, Thailand, Australia and New Zealand, with
the goal to be commercially active in at least three additional countries in
the next 12 months.
Altum is also pursuing high-THC
medical cannabis opportunities in Australia and New Zealand, where medicinal
cannabis is already legal in both countries, and intends to pursue recreational
cannabis opportunities in each of those countries should legalization
occur. Altum is well positioned to
capitalise on the medicinal cannabis opportunity in New Zealand via a 49%
interest in Kariki Pharma Limited (www.karikipharma.com). Kariki is a New
Zealand-domiciled medicinal cannabis company focused on creating a suite of
pharmaceutical quality medicinal cannabis for New Zealand, Australian, Asian,
and European patients and export markets.
New Zealand intends to hold a national referendum on the legalization of
the recreational use of cannabis on 19 September 2020.
"On the heels of our recent
investment in the Netherlands, our partnership with Altum represents another
meaningful step to leverage our three decades of experience in vertically
integrated, intensive agriculture, as well as our cannabis success in Canada,
for international CBD and cannabis opportunities," said Michael DeGiglio,
CEO, Village Farms International. "Village Farms is at a place where, with
well-established North American operations, continuously refined and enhanced
for optimized performance and growth, we are able to turn our attention to
strategic, early-stage international opportunities where CBD and cannabis are
being legalized in our pursuit of well-researched capital allocation for the
generation of outsized, long-term returns."
"With approximately 4.5 billion
people – more than four times that of the U.S., Canada and Europe combined –
the Asia-Pacific market represents one such sizeable but nascent opportunity,
with the addressable market for cannabis alone forecast to reach US$10 billion
by 2024. Altum is an outstanding
organization at the very forefront of the emerging CBD industry in the
Asia-Pacific region and represents a capital efficient means by which to
participate in this significant opportunity, as well as the legal medical, and
potentially the legal recreational, cannabis markets in Australia and New
Zealand."
Relevium
Technologies Inc. (TSXV: RLV) (OTC: RLLVF) announced that it has secured licenced a
patented science based nutraceutical formulation that addresses major points of
viral invasion, replication and toxicities develop by Dr. Dana F. Flavin, an
internationally-recognized expert in immune modulation and the prevention and
treatment of viruses and cancer.
The patented formulation developed
by Dr. Dana F. Flavin, which will be marketed under the Company’s Bioganix
brand, was developed to work with multiple pathways to combat viral infections,
including COVID-19, by increasing the antiviral defense while decreasing the
replication and toxicity of the virus.
According to Dr. Dana Flavin, the
most important aspect of a multiple pathway approach is synergy – a process in
which some substances cooperate to reach a combined effect that is greater than
the sum of their separate effect. Synergy is not only important in the
development of a specific effective formulation, but also as an adjunct to
conventional drug therapy.
The patented formulation was
designed the address viral infections through a synergistic interaction of
several natural and GRAS ingredients that amplify effect of ingredients working
with enhanced supportive mechanisms, which show greater efficacies based on
their expansion of the biochemical processes and pharmacological activities.
Based on research about specific
ingredients, the following natural substances offer important benefits in the
prevention and treatment of viral infection such as COVID-19. When combined,
their qualities are amplified for effectiveness.
N-acetylcysteine
(NAC)
added for its ability proven in clinical studies to increase lymphocytes that
contain interferon. Lymphocytes are often suppressed in viral infections like
COVID-19. These cells that release interferon are part of the Th1 lymphocytes
important for their antiviral activity. One of the mechanisms in this
lymphocyte suppression is the generation of a gas, nitric oxide. This gas comes
from an enzyme, nitric oxide synthase, and is elevated in viral infections. NAC
binds to this gas and allows the movement of these lymphocytes back into the
blood stream and an increased antiviral activity of these Th1 lymphocytes.
Additionally, NAC increases the endogenous anti-inflammatory factor,
glutathione, in the lung tissue.
Olive
Leaf Extract and Licorice Root added for their ability proven in
clinical studies to increase the release of interferon. One of the most
important mechanisms in viral defense is to increase interferon, which works
directly against virus replication and/or invasion. Many natural substances
increase the release of interferon. Combined, olive leaf extract and licorice
root are the most effective natural substances to increase this release of
interferon from the lymphocytes. Olive leaf contains essential substances like
polyphenols including oleuropein, which increases the release of interferon
lymphocytes. Olive leaf also increases the absolute numbers of the CD8+ and
natural killer cells to improve the defense against viral infections.
Additionally, licorice root with its glycyrrhinic acid, increases the release
of interferon. Licorice root has been used for hundreds of years to fight upper
respiratory viruses.
Zinc
added
for its ability proven in clinical studies to increase the efficacy of
interferon. Zinc is a known trace element that is imperative for the immune
system where it improves the host response to many infections and plays an
important role in the homeostasis of the immune system. In the cases of viral
infection, it increases the interferon efficacy to a multiple as much as
10-fold as well as having direct antiviral activities. Zinc supplementation
decreases the morbidity of lower respiratory tract infections in pediatric
patients in the developing world. In respiratory syncytial virus infections,
for example, zinc prevents the replication of the virus. With rhinoviruses,
zinc appears to inhibit the direct binding of the virus. Zinc also inhibits the
replication of human immunodeficiency virus type I (HIV-1); herpes simplex
virus (HSV); 0020vaccinia virus; and polioviruses.
Elderberry,
Vitamin C, and Lemon Balm added for their ability proven in clinical
studies to inhibit viral replication. One of the important nuclear
transcription factors involved in viral replication in coronavirus infections
is nuclear factor kappa B (NFKappaB). This key transcription factor activates
numerous genes involved in cellular immune response and inflammation. Many
studies have shown that NF-kappa B plays an important role in the pathogenesis
of lung diseases, and therefore, is important to inhibit this nuclear factor in
preventing and/or supporting patients with COVID-19. There are many
antioxidants that inhibit this important factor in viral replication. The most
important ones are Vitamin C, lemon balm and elderberry -- natural substances
that inhibit viral replication through their inhibition of NFKappaB. Additional
mechanisms that fight against viral infections include direct and indirect
immune activation, inhibition of viral replication, and even down regulating
toxic oxygen radicals involved in cell damage from viruses.
Cherry
Extract, Rose Hips and Nicotinamide added for their
ability proven in clinical studies to inhibit the oxygen radicals. The damage
caused by oxygen radicals in viral infections has been known for many years.
The major enzymes involved in this toxicity are xanthine oxidase (XO), NADPH
oxidase and inducible nitric oxide synthase (iNOS). The superoxide radical,
generated from XO and/or NADPH OX combine with the nitric oxide generated from
the iNOS to form the toxic product, peroxynitrite. Viruses, including
coronaviruses, are toxic via this pathway. These radicals are massively
destructive to tissues where they are generated. In the case of COVID-19, this
involves predominantly the lung tissue, causing a decrease in oxygen transfer
leading to major lung toxicity and hypoxia in multiple organs.
The Company has partnered with the
licensor, a Canadian company engaged in the research and development of
proprietary Nutraceutical products, Intellectual properties and other related
formulas for the health and wellness, nutraceutical industries and the general
public, to develop a strategy for brand development, messaging and retail
distribution.
Licensor has granted the Company an
initial exclusive license for the UNITED STATES, GERMANY and COLOMBIA to use
the Licensed Product and the Licensor Intellectual Property to manufacture,
have manufactured and sell the Licensed Product, provided that the Licensed
Product is manufactured in accordance with the specifications and quality
standards submitted or approved by Licensor.
Licensor grants licenses and rights
to the IP Rights and Marks through a base revenue share per unit sold of three
dollars. The Company has also agreed that the licensor will be working in
partnership with the Company to engage a third party or parties at it sole discretion , time and place for
the purpose of marketing, selling and promoting of such licensed products
through major retail chains where in this case that such collaboration will
result in a profit margin sharing.
CEO of Relevium Aurelio Useche
stated, “We are extremely excited to have secured the exclusive license for
this 100% natural synergistic and multi-pathway patented formulation, which we
will be launching in the market over the next months. This is a major addition
to the CleanCare product portfolio adding prevention and immunity support to
the Bioganix line of trusted nutraceuticals”
WeedMD
Inc.
(TSX-V:WMD) (OTCQX:WDDMF) announced that it has entered into an
exclusive licensing, manufacturing and distribution agreement with premium,
U.S.-based cannabis wellness house, MM Technology Holdings, LLC, owner of
Mary’s Brands, and the acclaimed product line, Mary’s Medicinals.
Under the terms of the Agreement, as
Mary’s sole Canadian partner, WeedMD will manufacture a suite of Mary’s
Medicinals’ products in-house with its own input biomass at its
state-of-the-art extraction hub CX Industries later this year. WeedMD will also
market, sell and distribute Mary’s Medicinals’ products across Canada’s
provincial adult-use and direct-to-consumer medical channels as it looks to
expand new cannabis offerings to address an underserved wellness and medical
market segment. Widely recognized for its innovative portfolio of delivery
methods, Mary’s suite of cannabis products includes transdermal gels and
patches and topicals.
“As we move into the next level of
product development, it’s imperative that we strategically partner with
established brands that share our core values and Mary's Brands offers a
superior product line that is backed by a team truly dedicated to ensuring the
quality, integrity and efficacy of its product offerings,” said Angelo
Tsebelis, CEO of WeedMD. “We’re proud to be selected as Mary’s exclusive
Canadian producer and distributor. With our cultivation platform and CX
extraction operations fully ramped-up, there's the added pride of developing
these renowned products in-house as we expand with new cannabis formats into a
lucrative, yet underserved consumer segment.”
“We’re thrilled to be partnering
with WeedMD and its CX extraction team as we execute on our long-term growth
strategy to expand the Mary’s Medicinals brand into Canada,” said Jacques
Panis, CEO of Mary’s Brands. “Our continued desire to innovate on additional
product offerings makes this partnership fitting as we look to collaborate with
a strong, experienced team that brings unparalleled expertise in cultivation
and extraction along with a proven ability to capture unique, next-level
distribution channels.”
Investor ideas reminds all
listeners to read our disclaimers and disclosures on the Investorideas.com
website and that this podcast is not an endorsement to buy products or services
or securities. Investors are reminded all investment involves risk and possible
loss of investment.
Learn more about
our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp
Hear Investor ideas cannabis potcast on iTunes
Hear the investor ideas potcast on Spotify
To hear more
Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.
Investorideas.com
podcasts are also available on iTunes,
Spotify, Google Play Music, Stitcher, Spreaker, YouTube via Spreaker, iHeartradio and Tunein.
Potcasts is now a certified
word mark Trademark on the blockchain through Cognate, Inc. CM
Certification-Registration Number: 10468217708
About Investorideas.com - News that
Inspires Big Investing Ideas
Investorideas.com
is a recognized news source publishing third party news, research and original
financial content. Learn about investing in stocks and sector trends with our
news alerts, articles, podcasts
and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech,
water, renewable energy and more. Investor Idea’s original branded content
includes the following podcasts and columns : Crypto
Corner , Play by Play sports and stock news column, Investor
Ideas Potcasts Cannabis News and Stocks on the Move podcast and
column, Cleantech and Climate Change , Exploring Mining the AI Eye .
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news,
articles and equity research as well as creates original content, including
video, interviews and articles. Original content created by investorideas is
protected by copyright laws other than syndication rights. Our site does not
make recommendations for purchases or sale of stocks, services or products.
Nothing on our sites should be construed as an offer or solicitation to buy or
sell products or securities. All investing involves risk and possible losses.
This site is currently compensated for news publication and distribution,
social media and marketing, content creation and more. Disclosure is posted for
each compensated news release, content published /created if required but
otherwise the news was not compensated for and was published for the sole
interest of our readers and followers. Contact management and IR of each
company directly regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our
other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to regulations
of each country. Please read Investorideas.com privacy policy:
https://www.investorideas.com/About/Private_Policy.asp
Investor Ideas does not condone the use of
cannabis except where permissible by law. Our site does not possess,
distribute, or sell cannabis products.
Follow us on Twitter https://twitter.com/Investorideas
Follow
us on Facebook https://www.facebook.com/Investorideas
Follow
us on YouTube https://www.youtube.com/c/Investorideas
Download
our Mobile App for
iPhone and Android
Join
our Investor Club https://www.investorideas.com/membership/
Contact Investorideas.com
800
665 0411
Get more Cannabis Stock Investor
Ideas – news, articles, podcasts and stock
directory
